Dr Richard Day
The gastrointestinal tract is essential for maintaining physiological homeostasis but has only a limited capacity to regenerate and repair in response to disease.
Our translational, interdisciplinary research is primarily focussed on applying principles of regenerative medicine to bowel function and other debilitating conditions as part of the UCL Grand Challenge of Human Wellbeing.
The primary research purpose of the group is to develop innovative therapeutic devices, for example for the treatment of gastrointestinal fistulas and faecal incontinence. Our research encompasses a 'bench to bedside' and 'bedside to bench' approach, with feedback sought from clinical staff and patients at an early stage during device development.
We have developed a novel microsphere-based scaffold and drug encapsulation/delivery technology that offers significant advantages over existing approaches for fistula repair. We are in the process of: 1) demonstrating that key features of the microspheres are retained when manufactured under GMP for clinical application; 2) demonstrating that the microspheres are safe to use in perianal fistulas through a first-in-man safety study; and 3) obtaining CE mark for this Class III medical device.
We have identified new composite bioactive materials for use in tissue engineering. We have shown that certain forms of bioactive glass are able to stimulate angiogenesis, a feature that can be utilized in regenerative medicine to promote integration of implanted scaffolds.
We are investigating the use of our microspheres as a platform technology to encapsulate and deliver growth factors and cells capable of promoting sphincter muscle growth for treatment of incontinence, as well as facilitating healing of chronic wounds elsewhere in the body.
We are conducting pioneering research into the innovative use of magnetic actuation to regenerate dysfunctional sphincter muscle, which, if successful, will provide a significant breakthrough in the treatment of incontinence.
Development of Rapid Prototypes for Muscle Augmentation Using Magnetic Augmentation
Development of novel stem cell-based therapies for aganglionic gut disorders
Gastrointestinal Regenerative Medicine
Novel therapies for gut disorders/diseases
I lead the Tissue Engineering Module (MECHGB07) on the MSc in Biomaterials & Tissue Engineering run by UCL Department of Mechanical Engineering (http://www.mecheng.ucl.ac.uk/learning/graduate/msc/biomaterials-tissue-engineering/).
I also teach on Allergy, Autoimmunity & Transplantation courses (INIM3006 and PATHG014) in the Division of Infection and Immunity, and on MSc/MEng courses in the Department of Biochemical Engineering.
My teaching interests include developing innovative methods for virtual learning environments that facilitate cross-discipline learning.
Dr Suwan Jayasinghe; Dr Gaetano Burriesci; Prof Quentin Pankhurst; Dr Simon Eaton; Dr Anton Emmanuel; Dr Paolo De Coppi; Dr Steven Howe; Dr Nikhil Thapar; Dr Alan Burns
- Riegler J, Liew A, Hynes S, Ortega D, O'Brien T, Day R, Richards T, Sharif F, Pankhurst Q, Lythgoe M (2013). Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials, 34(8), 1987 - 1994.
- Gonzalez-Molina J, Riegler J, Southern P, Ortega D, Frangos C, Angelopoulos Y, Husain S, Lythgoe M, Pankhurst Q, Day R (2012). Rapid Magnetic Cell Delivery for Large Tubular Bioengineered Constructs. Journal of the Royal Society Interface, 9(76), 3008 - 3016.
- Rasekh M, Ahmad Z, Frangos C, Bozec L, Edirisinghe M, Day R (2012). Spatial and Temporal Evaluation of Cell Attachment to Printed Polycaprolactone Microfibers. Acta Biomaterialia, 9(2), 5052 - 5062.
- Abou Neel E, Bozec L, Knowles JC, Syed O, Mudera V, Day R, Hyun JK (2012). Collagen - Emerging Collagen Based Therapies Hit the Patient. Advanced Drug Delivery Reviews, , - . doi:10.1016/j.addr.2012.08.010
- Rasekh M, Ahmad Z, Day R, Wickham A, Edirisinghe M (2011). Direct Writing of Polycaprolactone Polymer for Potential Biomedical Engineering Applications. Advanced Biomaterials, 13(9), B296 - B305.
- Day RM (2011). Functional Requirements of Wound Repair Biomaterials. In Farrar D (Ed.), Advanced Wound Repair Therapies (pp. 155 - 169). : Woodhead Publishing.
- Ahmadi R, Mordan N, Forbes A, Day RM (2011). Enhanced attachment, growth and migration of smooth muscle cells on microcarriers produced using thermally induced phase separation.. Acta Biomater, 7(4), 1542 - 1549. doi:10.1016/j.actbio.2010.12.022
- Rasekh M, Ahmad Z, Day R, Edirisinghe M (2011). Printing of Biocompatible Polymers and their Composites for Biomedical Engineering.
- Day RM (2010). Alimentary Tract. In Attala A, Lanza R, Thomson J, Nerem R (Ed.), Principles of Regenerative Medicine (pp. 925 - 941). : Academic Press. doi:10.1016/B978-0-12-381422-7.10050-1
- Keshaw H, Foong KS, Forbes A, Day RM (2010). Perianal Fistulae in Crohn’s Disease: Current and Future Approaches to Treatment. Inflammatory Bowel Diseases, 16(5), 870 - 880.
- Keshaw H, Thapar N, Burns AJ, Knowles J, Forbes A, Day RM (2010). Microporous collagen spheres produced via thermally induced phase separation for tissue regeneration. Acta Biomaterialia, 6(3), 1158 - 1166. doi:10.1016/j.actbio.2009.08.044
- Foong KS, Patel R, Forbes A, Day RM (2010). Anti-TNF-alpha-Loaded Microspheres as a Prospective Novel Treatment for Crohn's Disease Fistulae. Tissue Engineering, , 1 - 10. doi:10.1089/ten.tec.2009.0599
- Amadi A, Fagbemi A, Kelly P, Mwiya M, Torrente F, Salvestrini C, Day R, Golden M, Eklund E, Freeze H, Murch S (2009). Reduced production of sulfated glycosaminoglyans occurs in Zambian children with kwashiorkor but not marasmus. American Journal of Clinical Nutrition, 89, 592 - 600.
- Day R, Foong K, Goubareva I, Forbes A (2009). Fabrication and Assessment of Microspheres Loaded with Anti-TNF alpha as a Prospective Novel Treatment for Crohn's Disease Fistulae.
- Moosvi SR, Day R (2009). Bioactive glass modulation of intestinal epithelial cell restitution. Acta Biomaterialia, 5(1), 76 - 83.
- Keshaw H, Georgiou G, Blaker JJ, Forbes A, Knowles JC, Day RM (2009). Assessment of Polymer/Bioactive Glass-Composite Microporous Spheres for Tissue Regeneration Applications. Tissue Engineering: Part A, 15(7), 1451 - 1461. doi:10.1089/ten.tea.2008.0203
- Day R (2008). Biomaterials for Gastrointestinal Medicine, Repair and Reconstruction.. In Chu PK, Liu X (Ed.), Biomaterials Fabrication and Processing Handbook (pp. 633 - 658). : CRC Press.
- Blaker JJ, Pratten J, Ready D, Knowles JC, Forbes A, Day RM (2008). Assessment of antimicrobial microspheres as a prospective novel treatment targeted towards the repair of perianal fistulae. Aliment.Pharmacol.Ther., 28(5), 614 - 622.
- Day RM, Blaker J (2008). Porous Microspheres and Their Use in Therapy.
- Moosvi SR, Day RM (2008). Bioactive glass stimulates intestinal epithelial cell restitution.
- Blaker JJ, Knowles JC, Day RM (2008). Novel fabrication techniques to produce microspheres by thermally induced phase separation for tissue engineering and drug delivery. Acta Biomater., 4(2), 264 - 272.
- Day RM (2006). Epithelial stem cells and tissue engineered intestine. Curr.Stem Cell Res.Ther., 1(1), 113 - 120.
- Principi M, Day R, Marangi S, Burattini O, De F, V I, M P, A P, C F, A D, Leo A F, A I, E (2006). Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol.Immunotoxicol., 28(2), 185 - 195.
- Keshaw H, Sibbons PD, Forbes A, Day RM (2006). Development of a collagen-ceramic composite for fistula repair. Gut, 55, A86 - A87.
- Polymeros D, Bogdanos D, Day R, Arioli D, Vergani D, Forbes A (2006). Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?. Gastroenterology, 131(1), 85 - 96. doi:10.1053/j.gastro.2006.04.021
- Harbord MW, Marks DJ, Forbes A, Bloom SL, Day RM, Segal AW (2006). Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment.Pharmacol.Ther., 24(4), 651 - 660.
- Keshaw H, Sibbons PD, Forbes A, Day RM (2006). Development of a collagen-ceramic composite for fistula repair.
- Boccaccini AR, Blaker JJ, Maquet V, Day RM, Jerome R (2005). Preparation and characterisation of poly(lactide-co-glycolide) (PLGA) and PLGA/Bioglass((R)) composite tubular foam scaffolds for tissue engineering applications. Materials Science and Engineering: C, 25(1), 23 - 31.
- Day RM (2005). Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. Tissue Engineering, 11(5-6), 768 - 777. doi:10.1089/ten.2005.11.768
- Keshaw H, Forbes A, Day RM (2005). Release of angiogenic growth factors from cells encapsulated in alginate beads with bioactive glass. Biomaterials, 26(19), 4171 - 4179. doi:10.1016/j.biomaterials.2004.10.021
- Boccaccini A, Blaker JJ, Maquet V, Day RM, Jerome R (2005). Preparation and characterization of poly(lactide-co-glycolide) (PLGA) and PLGA/Bioglass® composite tubular foam scaffolds for tissue engineering applications. Mat.Sci.Eng.C, 25, 23 - 31.
- Day RM, Boccaccini A (2005). Effect of Particulate Bioactive Glasses on Human Macrophages In Vitro. J.Biomed.Mat.Res.Pt A, 73(1), 73 - 79.
- Day RM, Maquet V, Boccaccini AR, Jerome R, Forbes A (2005). In vitro and in vivo analysis of macroporous biodegradable poly(D,L-lactide-co-glycolide) scaffolds containing bioactive glass. J.Biomed.Mater.Res.A, 75(4), 778 - 787. doi:10.1002/jbm.a.30433
- Day RM, Boccaccini AR, Maquet V, Shurey S, Forbes A, Gabe SM, Jerome R (2004). In vivo characterisation of a novel bioresorbable poly(lactide-co-glycolide) tubular foam scaffold for tissue engineering applications. J.Mater.Sci.Mater.Med., 15(6), 729 - 734.
- Day RM, Boccaccini AR, Shurey S, Roether JA, Forbes A, Hench LL, Gabe SM (2004). Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. Biomaterials, 25(27), 5857 - 5866. doi:10.1016/j.biomaterials.2004.01.043
- Gabe S, Day R, Boccaccini A (2004). Tissue Engineering of the Intestine.. In Wnek GE, Bowlin GL (Ed.), Encyclopedia of Biomaterials and Biomedical Engineering (pp. - ). : Informa Healthcare.
- Shetty A, Forbes A, Day RM (2004). Does heparin restore epithelial gag expression in inflammatory bowel disease?.
- Day RM (2004). Bioactive Material for Use in Stimulating Vascularization.
- Blaker J, Day R, Maquet V, Boccaccini A (2004). Novel bioresorbable poly(lactide-co-glycolide) (PLGA) and PLGA/Bioglass® composite tubular foam scaffolds for tissue engineering applications. Mat.Sci.Forum, 455, 415 - 419.
- Hench LL, Boccaccini AR, Day RM, Gabe SM (2003). Third-generation gene-activating biomaterials. Thermec'2003, Pts 1-5, 426-4, 179 - 184.
- Day RM, Mitchell TJ, Knight SC, Forbes A (2003). Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine, 21(5), 224 - 233.
- Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Walker-Smith JA, Murch SH (2002). Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol.Psychiatry, 7(4), 375 - 82, 334.
- Day R, Boccaccini A, Roether J, Forbes A, Hench L, Gabe S (2002). The effect of Bioglass® on epithelial cell and fibroblast proliferation and incorporation into a PGA matrix.
- Harbord M, Day R, Hankin A, Bloom S, Forbes A, Segal A (2002). Neutrophil respiratory burst and tissue penetration are normal in Crohn’s disease during G-CSF administration.
- Day R, Harbord M, Segal A, Forbes A (2002). Differences in micro-vascular blood flow at sites of skin blisters may account for reduced leukocyte trafficking in Crohn’s disease.
- Day RM, Harbord M, Forbes A, Segal AW (2001). Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. Journal of Immunological Methods, 257(1-2), 213 - 220. doi:10.1016/S0022-1759(01)00467-7
- Loveless W, Feizi T, Valeri M, Day R, Bay S (2001). A monoclonal antibody, MIN/3/60, that recognises the sulpho-Lewisx and sulpho-Lewisa sequences detects a sub-population of epithelial glycans in the crypts of human colonic epithelium. Hybridoma, 20, 223 - 229.
- Furlano RI, Anthony A, Day R, Brown A, McGarvey L, Thomson MA, Davies SE, Berelowitz M, Forbes A, Wakefield AJ, Walker-Smith JA, Murch SH (2001). Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. The Journal of Pediatrics, 138(3), 366 - 372.
- Harbord M, Day R, Bloom S, Knight S, Forbes A, Segal A (2001). Neutrophil deficiency during acute inflammation in inflammatory bowel disease.
- Day R, Mitchell T, Knight S, Forbes A (2000). Suppression of epithelial syndecan-1 expression by tumour necrosis factor alpha.
- Westphal V, Murch SH, Soohyun K, Greetha S, Winchester B, Day R, Freeze HH (2000). Reduced heparan sulphate accumulaton in enterocytes contributes to protein losing enteropathy in a congenital disorder of glycosylation. American Journal of Pathology, 157, 1917 - 1925.
- Day R, Forbes A (1999). Serum basic fibroblast growth factor in inflammatory bowel disease.
- Day R, Talbot I, Forbes A (1999). Expression of the tri-molecular bFGF binding complex in inflammatory bowel disease.
- Day R, Forbes A (1999). Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet, 354(9172), 62 - 65.
- Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1999). Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig.Dis.Sci., 44(12), 2508 - 2515.
- Day RM, Hao X, Ilyas M, Daszak P, Talbot IC, Forbes A (1999). Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch., 434(2), 121 - 125.
- Day R, Forbes A (1998). Loss of heparan sulfate mediated basic fibroblast growth (bFGF) binding is restored by heparin.
- Day R, Forbes A (1998). Induced expression of syndecan-1 in reparative epithelium in vitro.
- Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1997). Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism for heparin therapy.
- Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1997). Expression of syndecan-1 and E-cadherin in inflammatory bowel disease.
- Day R, Daszak P, Forbes A (1997). Assessment of tight junction damage by inflammatory modulators using a model for junctional permeability studies.
- Day R, Hao XP, Ilyas M, Daszak P, Talbot I, Forbes A (1997). Changes in syndecan-1 immunoreactivity in the colorectal adenoma-carcinoma sequence.
- Day R, Forbes A (1997). Soluble E-cadherin measured by enzyme immunoassay in inflammatory bowel disease: a marker of disease activity and epithelial restitution?.
- Day R, Daszak P, Forbes A (1996). Differential ultrastructural changes in cultured HRT-18 cells after treatment with mesalamine and diclofenac.
- Abbasi A, Day R, Talbot I, McKeegan E, Forbes A (1995). Expression of cadherins (E & P), catenins ( & ) and desmosome in normal human colorectal mucosa and in colorectal tumours.
- Abbasi A, Day R, Talbot I, Forbes A (1995). Expression of CD44v6 and 17-1A in development and prognosis of colorectal cancer.
- Riegler J, Liew A, Hynes S, Ortega D, O’Brien T, Day R, Richards T, Sharif F, Pankhurst Q, Lythgoe M (). Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials, , - .
- Ghanbar H, Luo C, Bakhshi P, Day R, Edirisinghe M (). Preparation of Porous Microsphere-Scaffolds by Electrohydrodynamic Forming and Thermally Induced Phase Separation. Materials Science and Engineering C: Biomimetic and Supramolecular Systems, 33(5), 2488 - 2498. doi:10.1016/j.msec.2012.12.098
- Abou Neel EA, Bozec L, Knowles JC, Syed O, Mudera V, Day R, Hyun JK (). Collagen - Emerging Collagen Based Therapies Hit the Patient. Advanced Drug Delivery Reviews, , - .